GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thor Medical ASA (OSL:TRMED) » Definitions » Earnings per Share (Diluted)

Thor Medical ASA (OSL:TRMED) Earnings per Share (Diluted) : kr0.00 (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Thor Medical ASA Earnings per Share (Diluted)?

Thor Medical ASA's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was kr0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.00.

Thor Medical ASA's EPS (Basic) for the three months ended in Dec. 2023 was kr0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.00.

Thor Medical ASA's EPS without NRI for the three months ended in Dec. 2023 was kr0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.00.

During the past 3 years, the average EPS without NRIGrowth Rate was 82.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 57.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 12.10% per year.

During the past 13 years, Thor Medical ASA's highest 3-Year average EPS without NRI Growth Rate was 82.40% per year. The lowest was -93.60% per year. And the median was -13.20% per year.


Thor Medical ASA Earnings per Share (Diluted) Historical Data

The historical data trend for Thor Medical ASA's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thor Medical ASA Earnings per Share (Diluted) Chart

Thor Medical ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.45 -5.91 -4.65 -2.70 -0.15

Thor Medical ASA Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.93 -0.79 - - -

Competitive Comparison of Thor Medical ASA's Earnings per Share (Diluted)

For the Biotechnology subindustry, Thor Medical ASA's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thor Medical ASA's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thor Medical ASA's PE Ratio distribution charts can be found below:

* The bar in red indicates where Thor Medical ASA's PE Ratio falls into.



Thor Medical ASA Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Thor Medical ASA's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-26.561-0)/174.787
=-0.15

Thor Medical ASA's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(0-0)/174.787
=0.00

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Thor Medical ASA  (OSL:TRMED) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Thor Medical ASA Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Thor Medical ASA's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Thor Medical ASA (OSL:TRMED) Business Description

Traded in Other Exchanges
Address
Kjelsasveien 168 B, Oslo, NOR, 0884
Nordic Nanovector ASA is a biopharmaceutical company. It is engaged in the development and commercialization of targeted therapeutics to improve the lives of patients with haematological cancers, such as non-Hodgkin lymphoma and leukaemia. The company's main clinical stage product is Betalutin.

Thor Medical ASA (OSL:TRMED) Headlines

No Headlines